Dr. Leo I. Gordon, MD

Dr. Gordon practices at Northwestern Medical Group in Chicago, Illinois.

Dr. Gordon's NPI, 1821028499, was assigned on July 3, 2006. Dr. Gordon graduated from University Of Cincinnati College Of Medicine in 1973. Dr. Gordon holds Illinois license 036050052.

Dr. Gordon's primary practice is Northwestern Medical Group, at 675 N Saint Clair St Ste 19-100 Suite 19-100, Chicago, IL 60611. The practice phone is (312) 664-3278.

Dr. Gordon's primary practice is Northwestern Medical Group in Chicago, Illinois. Dr. Gordon is also affiliated with Northwestern Memorial Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Gordon to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gordon practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Gordon's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Gordon is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Gordon's licenses on file in 2 states: Illinois and Minnesota.

Dmand AI lists chronic anemia, chronic leukemia, immune deficiency disease, lymphoma and multiple myeloma among the conditions Dr. Gordon treats.

CMS data shows 8,611 Medicare services from Dr. Gordon across 21 procedure codes in 2024, for 519 Medicare patients. Medicare paid $297,530 for them.

CMS counts 519 Medicare patients who saw Dr. Gordon in 2024. The largest group is 65 to 74, with 235 patients. 69% of them have high cholesterol, and 66% have high blood pressure. 9% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gordon's median patient age at 73, with 46% women.

In 2024, Dr. Gordon wrote 204 Medicare Part D claims for 56 patients. 55% of them were for generic drugs. CMS names the drug for 120 of them, across 5 drugs with 11 or more claims each, at $922,906 in total drug cost. In 2023, CMS named 83 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Gordon for performance year 2024, reported through an alternative payment model (APM). Dr. Gordon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gordon as offering telehealth.

Dmand AI links 258 papers to Dr. Gordon, published from 2004 to 2025. 2016 was the busiest year, with 11. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Non-Hodgkin and Lymphoma, Large B-Cell, Diffuse. Dr. Gordon has published most often in Leuk Lymphoma. Dr. Gordon's most frequent co-authors are Leo Gordon, MD, Jane N. Winter, MD and Reem Md Karmali, MD.

Dmand AI links Dr. Gordon to 6 clinical trials, 3 of them phase 1/2 studies. Conditions studied include Lymphoma, Burkitt Lymphoma and Hodgkin Disease. Northwestern University sponsors the most, 5.

CMS Open Payments shows 66 general payments to Dr. Gordon from 16 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 84% of the total. Celgene Corporation paid the most, $11,050.

Dmand AI lists 4 awards for Dr. Gordon, most recently Checkbook Top Doc in 2011.

Dr. Gordon graduated from University Of Cincinnati College Of Medicine in 1973. Dr. Gordon is a member of ACP.

Dr. Gordon is in network with 16 carriers, including Aetna, HCSC and Cigna. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.